<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="638">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179373</url>
  </required_header>
  <id_info>
    <org_study_id>10003</org_study_id>
    <nct_id>NCT01179373</nct_id>
  </id_info>
  <brief_title>Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease</brief_title>
  <official_title>Phase 2 Study of Trans Cranial Magnetic Stimulation as Additional Therapy Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the ability of Transcranial Magnetic&#xD;
      Stimulation with H coil to prefrontal cortex , with an addition of cognitive brain training,&#xD;
      to improve cognitive performance in patients with Alzheimer's disease which received drug&#xD;
      treatment. This study is a single-center, double-blind 4 months duration trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome measure: ADAS-COG (time frame baseline, 2 months, 4 months) Secondary outcome&#xD;
      measure: CGI-C,FAB, ADL, Neuropsychological computerized test(time frame baseline, 2 months,&#xD;
      4 months.&#xD;
&#xD;
      Estimated enrollment: 40 patients Estimated Study start Date: November 2008 Estimated Study&#xD;
      Completion date: November 2009 Number of arms: 2&#xD;
&#xD;
      Ages: 50-85 Genders: both&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive functioning score by ADAS-COG</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global advancement score by CGI-C</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal lobe functioning score by FAB</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily activity score by ADL</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>TMS, High Frequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Frequency TMS with H coil to prefrontal cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS, Low Frequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Frequency TMS to Prefrontal cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham TMS with H Coil on Prefrontal Cortex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS, H coil</intervention_name>
    <description>TMS, H Coil, High/ Low Frequency</description>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_label>TMS, High Frequency</arm_group_label>
    <arm_group_label>TMS, Low Frequency</arm_group_label>
    <other_name>TransCranial Magnetic Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged 50-85.&#xD;
&#xD;
          2. Diagnosed with Alzheimer's disease for at least one year (by the DSM-IV criteria).&#xD;
&#xD;
          3. Scored below 24 on the MMSE.&#xD;
&#xD;
          4. Received drug therapy for their disease, with each treatment having been administered&#xD;
             at an acceptable dosage for at least 5 weeks, with either no effect or only partial&#xD;
             response.&#xD;
&#xD;
          5. Answered in the negative to all questions in the pre-TMS treatment safety&#xD;
             questionnaire.&#xD;
&#xD;
          6. Gave their oral and written consent to participate in the trial.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. An additional neurological or psychiatric disorder.&#xD;
&#xD;
          2. Severe personality disorder.&#xD;
&#xD;
          3. Uncontrolled hypertension.&#xD;
&#xD;
          4. History of epilepsy, seizure, or heat convulsion.&#xD;
&#xD;
          5. History of epilepsy or seizure in first degree relatives.&#xD;
&#xD;
          6. History of head injury or stroke.&#xD;
&#xD;
          7. History of metal implants in the head (except dental fillings).&#xD;
&#xD;
          8. History of surgery entailing metallic implants or known history of any metallic&#xD;
             particles in the eye, implanted cardiac pacemaker, cochlear implants, use of&#xD;
             neurostimulators, or any medical pumps.&#xD;
&#xD;
          9. History of migraines in the last six months.&#xD;
&#xD;
         10. History of drug or alcohol abuse.&#xD;
&#xD;
         11. Inadequate communication with examiner.&#xD;
&#xD;
         12. Participation in another clinical study, either concurrent with this trial or in the 3&#xD;
             months preceding it.&#xD;
&#xD;
         13. Inability to sign a consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merchav Clinics</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>August 8, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

